Rankings
▼
Calendar
SLNO FY 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
SLNO
Soleno Therapeutics, Inc.
$2B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$190M
Gross Profit
$188M
98.6% margin
Operating Income
$15M
7.9% margin
Net Income
$21M
11.0% margin
EPS (Diluted)
$0.39
Cash Flow
Operating Cash Flow
$47M
Free Cash Flow
$47M
Stock-Based Comp.
$46M
Balance Sheet
Total Assets
$564M
Total Liabilities
$114M
Stockholders' Equity
$450M
Cash & Equivalents
$70M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$190M
$0
—
Gross Profit
$188M
$0
—
Operating Income
$15M
-$188M
+108.0%
Net Income
$21M
-$176M
+111.9%
← Q4 2024
All Quarters
Q1 2025 →